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Abstract
Background: Major histocompatibility complex class II deficiency, also referred to as bare lymphocyte syndrome is
a rare primary Immunodeficiency disorder characterized by a profondly deficient human leukocyte antigen class II
expression and a lack of cellular and humoral immune responses to foreign antigens. Clinical manifestations
include extreme susceptibility to viral, bacterial, and fungal infections. The infections begin in the first year of life
and involve usually the respiratory system and the gastrointestinal tract. Severe malabsorption with failure to thrive
ensues, often leading to death in early childhood. Bone marrow transplantation is the curative treatment.
Case reports: Here we report two cases with a late outcome MHC class II deficiency. They had a long term history
of recurrent bronchopulmonary and gastrointestinal infections. Bone marrow transplantation could not be
performed because no compatible donor had been identified. At the age of 12 years, they developed oral
papillomatous lesions related to HPV (human papillomavirus). The diagnosis of HPV infection was done by
histological examination. HPV typing performed on the tissue obtained at biopsy showed HPV type 6. The lesions
were partially removed after two months of laser treatment.
Conclusions: Viral infections are common in patients with MHC class II and remain the main cause of death.
Besides warts caused by HPV infection do not exhibit a propensity for malignant transformation; they can cause
great psychosocial morbidity.
Case presentations
Case 1
A 22-year-old girl, born from unrelated healthy parents
of Tunisian origin, during the neonatal period had
received BCG immunization without any local or sys-
temic responses. From 6 months of age she had recurrent
episodes of bronchopulmonary and gastrointestinal infec-
tions. At 10 years, she was referred to our hospital for the
first time. On physical examination, she was growth
retarded with a weight of 20 kg (-2.2SD) and height of
121 cm (-2SD). Tuberculin skin test was negative. Immu-
nologic examination revealed decreased serum IgG levels:
5 g/l (5.6-16.1), low serum IgA: 0.4 g/l (0.5-2.5), and
serum IgM levels within the normal range of age: 0.8 g/l
(0.5-1.8). Lymphocyte subsets produced the following:
CD3 =2×1 0
9cells/L (1.2-2.6), CD4 =1×1 0
9cells/L
(0.65-1.5), CD8 =1×1 0
9cells/L (0.37-1.1), CD19 = 0.374
×1 0
9cells/L (0.27-0.86). The diagnosis of MHC class II
deficiency was established on the basis of the loss of
MHC II expression on peripheral blood lymphocytes and
PHA activated T cells related to homozygous 752delG25
mutation in the RFXANK gene (Figure 1). She was
started on intravenous immunoglobulin (0.4 g/kg by 3
weeks) and cotrimoxazole sulfamethoxazole prophylaxis
(25 mg/kg, 3 times a week). Bone marrow transplantation
could not be performed because no compatible donor
was identified. At the age of 12, she had multiple, pale,
painless, lesions on her buccal mucosa (Figure 2). The
lesions were firm on palpation, covered by healthy, nor-
mal appearing mucosa, neither ulcerated nor inflamed,
but her dental hygiene was poor. Sexual abuse was
denied by the patient. A biopsy of the oral lesions with
histological examination was performed; HPV infection
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obtained at biopsy showed HPV type 6. HLA typing
revealed an HLA DQB1*0301phenotype. The patient was
treated by laser with partial response. She has a Kar-
nofsky Performance Scale Index score of 50%.
Case 2
A 19-year-old girl, the sister of the index case, had had
an uneventful clinical course from birth since the sixth
month of life when she has suffered from chronic diar-
rhea and recurrent bronchopulmonary infections with
bronchiectasis. Immunologic examination revealed
decreased serum IgG levels: 4.5 g/l (5.6-16.1), low serum
IgA: 0.46 g/l (0.5-2.5), and serum IgM levels within the
normal range for age: 0.8 g/l (0.5-1.8). Lymphocytes sub-
sets produced the following: CD3 = 2.7 × 10
9cells/L (1.2-
2.6), CD4 =1 . 4×1 0
9cells/L (0.65-1.5), CD8 =1 . 6 5×
10
9cells/L (0.37-1.1), CD19 =0 . 4 6×1 0
9cells/L (0.27-
0.86). The diagnosis of MHC class II deficiency was
based on the family and personal history of recurrent
and severe infections, and was confirmed at six years of
life when she was referred to our hospital. Immunologic
examination revealed a defect of HLA-DR expression
comparable to that in her sister. The molecular analysis
identified the same homozygous 752delG26 mutation in
the RFXANK genes. Intravenous immunoglobulin (0.4
g/kg every 3 weeks) and cotrimoxazole sulfamethoxazole
prophylaxis (25 mg/kg, 3 times a week) were initiated
after this diagnosis. Bone marrow transplantation could
not be performed because no compatible donor had
been identified. Her symptoms improved between the
ages of 5 and 12 years, with a decrease in the frequency
and severity of infections. At the age of 12, exophytic
and cauliflower papillomatous lesions appeared with
clear contours at labial and buccal mucous membrane,
without other inflammatory lesions (Figure 3). These
lesions were not associated with dysphagia, odynophagia
or respiratory problems; HPV typing performed on the
tissue obtained at biopsy showed HPV type 6. HLA typ-
ing revealed an HLA DQB1*0301phenotype. The lesions
were partially removed after two months of laser treat-
ment. She has a Karnofsky Performance Scale Index
score of 50%.
Figure 1 RFXANK mutation.
 
Figure 2 Disseminated warts on oral cavity.
 
Figure 3 Inferior intern lip (right side).
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Lymphocyte major histocompatibility complex (MHC)
class II deficiency also referred to as the bare lymphocyte
syndrome, is a rare autosomal recessive primary com-
bined immunodeficiency syndrome that accounts for 5%
of all cases of severe combined immunodeficiency and
characterized by a defective expression of human leuco-
cyte antigen (HLA) class II molecules due to mutations
in four different MHC II regulatory genes (CIITA,
RFXANK, RFX5, RFXAP) [1]. More than 150 patients
have been reported worldwide, most of them were origi-
nated from North Africa where the frequency of consan-
guineous marriages is high [2,3]. Half of the reported
cases have RFXANK deficiency [2-4]. Clinical manifesta-
tions appear early in life including susceptibility to infec-
tions, primarily of the respiratory and gastrointestinal
tract and severe malabsorption with failure to thrive
often leading to death in early childhood [5,6]. Supportive
treatment includes intravenous immunoglobulin and
prophylaxis against Pneumocystis Jovecci. This therapy
results in a marked decrease in the number of bacterial
infectious episodes. MHC class II deficiency has a poor
p r o g n o s i s ,w i t hal i f ee x p e c t a n c yo fo n l yaf e wy e a r s[ 7 ] .
The only curative approach known to date is allogeneic
haematopoietic stem cell transplantation [8]. Few
patients survive beyond the age of 20 years under regular
immunoglobulin substitution and prophylactic antibio-
tics. Unknown genetic factors may influence innate or
CD8-T cell-mediated immunity, potentially accounting
for this more favorable outcome. Genetic predisposition
factors and environmental factors such as medical care
and family hygiene may be responsible for differences in
the clinical expression of the disease state [9]. Affected
patients are extremely susceptible to persistent and
recurrent viral infections. The most frequent viral infec-
tions include Cytomegalovirus, enterovirus, adenovirus
and herpes simplex virus [4]. MHC class II deficiency
patients are at increased risk of oral HPV infection.
Negative tuberculin skin test, lymphopenia, and the low
CD4+ T cell count indicated that our patients had defects
in cellular immunity, which lead to the HPV infection.
Genetic factors, malnutrition, and poor hygiene are also
found to be associated with this infection. Accompanying
features such as growth retardation and poor oral
hygiene of our patients might have been facilitating fac-
tors. According to other studies [10,11], the major histo-
compatibility complex might contribute to the HPV
infection, however HLA typing of our patients revealed
an HLA DQB1*0301phenotype. HPV infection has
attracted a great deal of attention, not just because of the
difficulty of managing oral warts but also because of the
oncogenic potential of certain strains [12]. HPV has been
implicated as a cause of several types of benign oral
lesions grouped clinically as oral warts. Oral warts can
present in almost any location in the mouth as nodular
or raised lesions that appear pink or white depending on
the degree of keratinization. The majority of these lesions
are the result of HPV 6 and 11 [13]. HPV types 6 and 11
are typically labeled as low risk because infection with
these types has low oncogenic potential and usually
results in the formation of condylomata and low-grade
precancerous lesions. Several treatment options are used
to remove oral warts including electro or radiodisseca-
tion, laser surgery, cryotherapy, or surgical excision but
no treatment is completely satisfactory; relapse is fre-
quent and requires re-treatment [14]. The lesions of our
patients were partially removed by laser surgery.
Conclusions
Viral infections are commonly reported in patients with
combined immunodeficiency. These reports add to the
list of serious infections occurring in association with
MHC class II deficiency. Allogeneic hematopoietic stem
cell transplantation is the only therapeutic option avail-
able for patients with MHC class II deficiency.
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